Drugs / IGC AD1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04749563 Comparator | Jan → Jun 2021 | Alzheimer disease | IGC Pharma, LLC | Completed | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | IGC Pharma, LLC | IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances igcpharma.com ↗ |
| 2026-02-02 | IGC Pharma, LLC | IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation igcpharma.com ↗ |
| 2026-01-05 | IGC Pharma, LLC | IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial igcpharma.com ↗ |
| 2025-11-13 | IGC Pharma, LLC | USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer’s Disease and Central Nervous System Disorders igcpharma.com ↗ |
| 2024-04-26 | IGC Pharma, LLC | IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation igcpharma.com ↗ |
| 2024-03-19 | IGC Pharma, LLC | IGC Pharma Advances in Alzheimer’s Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1 igcpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGC-AD1 | “Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease” NCT04749563 ↗ |
| Route | Oral | “IGC AD1 oral Solution” NCT04749563 ↗ |